Selected research
Market Structure
Global Mycosis Fungoides Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032
Market perspective
The global Mycosis Fungoides Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The US & Canada market for Mycosis Fungoides Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The Europe market for Mycosis Fungoides Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Mycosis Fungoides Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
The China market for Mycosis Fungoides Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global manufacturers of Mycosis Fungoides Therapeutics include Kyowa Kirin Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck & Co. Inc., Soligenix Inc., Seattle Genetics Inc., Horizon Therapeutics Plc, Helsinn Healthcare SA and Celgene Corp., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Includes
This report provides an overview of the global Mycosis Fungoides Therapeutics market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.
The study covers key producers of Mycosis Fungoides Therapeutics and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.
The report also presents Mycosis Fungoides Therapeutics revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.
In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Mycosis Fungoides Therapeutics market size, projected growth trends, production technologies, key applications, and end-use industries.
Mycosis Fungoides Therapeutics Segment by Company
Kyowa Kirin Co. Ltd.
Takeda Pharmaceutical Co. Ltd.
Eisai Co. Ltd.
Merck & Co. Inc.
Soligenix Inc.
Seattle Genetics Inc.
Horizon Therapeutics Plc
Helsinn Healthcare SA
Celgene Corp.
Azurity Pharmaceuticals Inc.
Mycosis Fungoides Therapeutics Segment by Type
Small Molecules
Biologics
Mycosis Fungoides Therapeutics Segment by Application
Hospital
Clinic
Other
Mycosis Fungoides Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mycosis Fungoides Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mycosis Fungoides Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mycosis Fungoides Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Mycosis Fungoides Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Mycosis Fungoides Therapeutics industry.
Chapter 3: Detailed analysis of Mycosis Fungoides Therapeutics companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Mycosis Fungoides Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 8: Europe by type, by application and by country, revenue for each segment.
Chapter 9: China by type, and by application, revenue for each segment.
Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.
Chapter 12: Concluding Insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Small Molecules
- Biologics
Applications
- Hospital
- Clinic
- Other
Companies covered
- Kyowa Kirin Co. Ltd.
- Takeda Pharmaceutical Co. Ltd.
- Eisai Co. Ltd.
- Merck & Co. Inc.
- Soligenix Inc.
- Seattle Genetics Inc.
- Horizon Therapeutics Plc
- Helsinn Healthcare SA
- Celgene Corp.
- Azurity Pharmaceuticals Inc.
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Market Analysis by Type
- 1.2.1 Global Mycosis Fungoides Therapeutics Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
- 1.2.2 Small Molecules
- 1.2.3 Biologics
- 1.3 Market Analysis by Application
- 1.3.1 Global Mycosis Fungoides Therapeutics Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Clinic
- 1.3.4 Other
- 1.4 Global Market Growth Prospects
- 1.5 Global Mycosis Fungoides Therapeutics Growth Trends by Region
- 1.5.1 Global Mycosis Fungoides Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 1.5.2 Mycosis Fungoides Therapeutics Market Size by Region (2021-2026)
- 1.5.3 Mycosis Fungoides Therapeutics Market Size by Region (2027-2032)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 1.8 Years Considered
2 Global Mycosis Fungoides Therapeutics Market Dynamics
- 2.1 Mycosis Fungoides Therapeutics Industry Trends
- 2.2 Mycosis Fungoides Therapeutics Industry Drivers
- 2.3 Mycosis Fungoides Therapeutics Industry Opportunities and Challenges
- 2.4 Mycosis Fungoides Therapeutics Industry Restraints
3 Competitive Landscape by Company
- 3.1 Global Mycosis Fungoides Therapeutics Revenue by Company (2021-2026)
- 3.2 Global Mycosis Fungoides Therapeutics Players Revenue Ranking, 2024 VS 2025 VS 2026
- 3.3 Global Mycosis Fungoides Therapeutics Key Company Head office and Area Served
- 3.4 Global Mycosis Fungoides Therapeutics Company, Product Type & Application
- 3.5 Global Mycosis Fungoides Therapeutics Company Establishment Date
- 3.6 Market Competitive Analysis
- 3.6.1 Global Mycosis Fungoides Therapeutics Market CR5 and HHI
- 3.6.2 Global Top 5 and 10 Mycosis Fungoides Therapeutics Players Market Share by Revenue in 2025
- 3.6.3 2025 Mycosis Fungoides Therapeutics Tier 1, Tier 2, and Tier 3
4 Mycosis Fungoides Therapeutics Market by Type
- 4.1 Global Mycosis Fungoides Therapeutics Market Size by Type (2021 VS 2025 VS 2032)
- 4.2 Global Mycosis Fungoides Therapeutics Market Size by Type (2021-2032)
- 4.3 Global Mycosis Fungoides Therapeutics Market Size Share by Type (2021-2032)
5 Mycosis Fungoides Therapeutics Market by Application
- 5.1 Global Mycosis Fungoides Therapeutics Market Size by Application (2021 VS 2025 VS 2032)
- 5.2 Global Mycosis Fungoides Therapeutics Market Size by Application (2021-2032)
- 5.3 Global Mycosis Fungoides Therapeutics Market Size Share by Application (2021-2032)
6 Company Profiles
- 6.1 Kyowa Kirin Co. Ltd.
- 6.1.1 Kyowa Kirin Co. Ltd. Company Information
- 6.1.2 Kyowa Kirin Co. Ltd. Business Overview
- 6.1.3 Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.1.4 Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
- 6.1.5 Kyowa Kirin Co. Ltd. Recent Developments
- 6.2 Takeda Pharmaceutical Co. Ltd.
- 6.2.1 Takeda Pharmaceutical Co. Ltd. Company Information
- 6.2.2 Takeda Pharmaceutical Co. Ltd. Business Overview
- 6.2.3 Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.2.4 Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
- 6.2.5 Takeda Pharmaceutical Co. Ltd. Recent Developments
- 6.3 Eisai Co. Ltd.
- 6.3.1 Eisai Co. Ltd. Company Information
- 6.3.2 Eisai Co. Ltd. Business Overview
- 6.3.3 Eisai Co. Ltd. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.3.4 Eisai Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
- 6.3.5 Eisai Co. Ltd. Recent Developments
- 6.4 Merck & Co. Inc.
- 6.4.1 Merck & Co. Inc. Company Information
- 6.4.2 Merck & Co. Inc. Business Overview
- 6.4.3 Merck & Co. Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.4.4 Merck & Co. Inc. Mycosis Fungoides Therapeutics Product Portfolio
- 6.4.5 Merck & Co. Inc. Recent Developments
- 6.5 Soligenix Inc.
- 6.5.1 Soligenix Inc. Company Information
- 6.5.2 Soligenix Inc. Business Overview
- 6.5.3 Soligenix Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.5.4 Soligenix Inc. Mycosis Fungoides Therapeutics Product Portfolio
- 6.5.5 Soligenix Inc. Recent Developments
- 6.6 Seattle Genetics Inc.
- 6.6.1 Seattle Genetics Inc. Company Information
- 6.6.2 Seattle Genetics Inc. Business Overview
- 6.6.3 Seattle Genetics Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.6.4 Seattle Genetics Inc. Mycosis Fungoides Therapeutics Product Portfolio
- 6.6.5 Seattle Genetics Inc. Recent Developments
- 6.7 Horizon Therapeutics Plc
- 6.7.1 Horizon Therapeutics Plc Company Information
- 6.7.2 Horizon Therapeutics Plc Business Overview
- 6.7.3 Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.7.4 Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Product Portfolio
- 6.7.5 Horizon Therapeutics Plc Recent Developments
- 6.8 Helsinn Healthcare SA
- 6.8.1 Helsinn Healthcare SA Company Information
- 6.8.2 Helsinn Healthcare SA Business Overview
- 6.8.3 Helsinn Healthcare SA Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.8.4 Helsinn Healthcare SA Mycosis Fungoides Therapeutics Product Portfolio
- 6.8.5 Helsinn Healthcare SA Recent Developments
- 6.9 Celgene Corp.
- 6.9.1 Celgene Corp. Company Information
- 6.9.2 Celgene Corp. Business Overview
- 6.9.3 Celgene Corp. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.9.4 Celgene Corp. Mycosis Fungoides Therapeutics Product Portfolio
- 6.9.5 Celgene Corp. Recent Developments
- 6.10 Azurity Pharmaceuticals Inc.
- 6.10.1 Azurity Pharmaceuticals Inc. Company Information
- 6.10.2 Azurity Pharmaceuticals Inc. Business Overview
- 6.10.3 Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (US$ Million) & (2021-2026)
- 6.10.4 Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Product Portfolio
- 6.10.5 Azurity Pharmaceuticals Inc. Recent Developments
7 North America
- 7.1 North America Mycosis Fungoides Therapeutics Market Size (2021-2032)
- 7.2 North America Mycosis Fungoides Therapeutics Market Size by Type
- 7.2.1 North America Mycosis Fungoides Therapeutics Market Size by Type (2021-2026)
- 7.2.2 North America Mycosis Fungoides Therapeutics Market Size by Type (2027-2032)
- 7.2.3 North America Mycosis Fungoides Therapeutics Market Share by Type (2021-2032)
- 7.3 North America Mycosis Fungoides Therapeutics Market Size by Application
- 7.3.1 North America Mycosis Fungoides Therapeutics Market Size by Application (2021-2026)
- 7.3.2 North America Mycosis Fungoides Therapeutics Market Size by Application (2027-2032)
- 7.3.3 North America Mycosis Fungoides Therapeutics Market Share by Application (2021-2032)
- 7.4 North America Mycosis Fungoides Therapeutics Market Size by Country
- 7.4.1 North America Mycosis Fungoides Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 7.4.2 North America Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 7.4.3 North America Mycosis Fungoides Therapeutics Market Size by Country (2027-2032)
- 7.4.4 North America Mycosis Fungoides Therapeutics Market Share by Country (2021-2032)
- 7.4.5 United States
- 7.4.6 Canada
- 7.4.7 Mexico
8 Europe
- 8.1 Europe Mycosis Fungoides Therapeutics Market Size (2021-2032)
- 8.2 Europe Mycosis Fungoides Therapeutics Market Size by Type
- 8.2.1 Europe Mycosis Fungoides Therapeutics Market Size by Type (2021-2026)
- 8.2.2 Europe Mycosis Fungoides Therapeutics Market Size by Type (2027-2032)
- 8.2.3 Europe Mycosis Fungoides Therapeutics Market Share by Type (2021-2032)
- 8.3 Europe Mycosis Fungoides Therapeutics Market Size by Application
- 8.3.1 Europe Mycosis Fungoides Therapeutics Market Size by Application (2021-2026)
- 8.3.2 Europe Mycosis Fungoides Therapeutics Market Size by Application (2027-2032)
- 8.3.3 Europe Mycosis Fungoides Therapeutics Market Share by Application (2021-2032)
- 8.4 Europe Mycosis Fungoides Therapeutics Market Size by Country
- 8.4.1 Europe Mycosis Fungoides Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 8.4.2 Europe Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 8.4.3 Europe Mycosis Fungoides Therapeutics Market Size by Country (2027-2032)
- 8.4.4 Europe Mycosis Fungoides Therapeutics Market Share by Country (2021-2032)
- 8.4.5 Germany
- 8.4.6 France
- 8.4.7 U.K.
- 8.4.8 Italy
- 8.4.9 Russia
- 8.4.10 Nordic Countries
9 China
- 9.1 China Mycosis Fungoides Therapeutics Market Size (2021-2032)
- 9.2 China Mycosis Fungoides Therapeutics Market Size by Type
- 9.2.1 China Mycosis Fungoides Therapeutics Market Size by Type (2021-2026)
- 9.2.2 China Mycosis Fungoides Therapeutics Market Size by Type (2027-2032)
- 9.2.3 China Mycosis Fungoides Therapeutics Market Share by Type (2021-2032)
- 9.3 China Mycosis Fungoides Therapeutics Market Size by Application
- 9.3.1 China Mycosis Fungoides Therapeutics Market Size by Application (2021-2026)
- 9.3.2 China Mycosis Fungoides Therapeutics Market Size by Application (2027-2032)
- 9.3.3 China Mycosis Fungoides Therapeutics Market Share by Application (2021-2032)
10 Asia (Excluding China)
- 10.1 Asia Mycosis Fungoides Therapeutics Market Size (2021-2032)
- 10.2 Asia Mycosis Fungoides Therapeutics Market Size by Type
- 10.2.1 Asia Mycosis Fungoides Therapeutics Market Size by Type (2021-2026)
- 10.2.2 Asia Mycosis Fungoides Therapeutics Market Size by Type (2027-2032)
- 10.2.3 Asia Mycosis Fungoides Therapeutics Market Share by Type (2021-2032)
- 10.3 Asia Mycosis Fungoides Therapeutics Market Size by Application
- 10.3.1 Asia Mycosis Fungoides Therapeutics Market Size by Application (2021-2026)
- 10.3.2 Asia Mycosis Fungoides Therapeutics Market Size by Application (2027-2032)
- 10.3.3 Asia Mycosis Fungoides Therapeutics Market Share by Application (2021-2032)
- 10.4 Asia Mycosis Fungoides Therapeutics Market Size by Country
- 10.4.1 Asia Mycosis Fungoides Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 10.4.2 Asia Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 10.4.3 Asia Mycosis Fungoides Therapeutics Market Size by Country (2027-2032)
- 10.4.4 Asia Mycosis Fungoides Therapeutics Market Share by Country (2021-2032)
- 10.4.5 Japan
- 10.4.6 South Korea
- 10.4.7 Taiwan
- 10.4.8 Southeast Asia
- 10.4.9 India
- 10.4.10 Australia
11 South America, Middle East & Africa
- 11.1 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Size (2021-2032)
- 11.2 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Type
- 11.2.1 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Type (2021-2026)
- 11.2.2 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Type (2027-2032)
- 11.2.3 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Share by Type (2021-2032)
- 11.3 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Application
- 11.3.1 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Application (2021-2026)
- 11.3.2 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Application (2027-2032)
- 11.3.3 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Share by Application (2021-2032)
- 11.4 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Country
- 11.4.1 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Country (2021 VS 2025 VS 2032)
- 11.4.2 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Country (2021-2026)
- 11.4.3 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Size by Country (2027-2032)
- 11.4.4 South America, Middle East & Africa Mycosis Fungoides Therapeutics Market Share by Country (2021-2032)
- 11.4.5 Brazil
- 11.4.6 South Africa
- 11.4.7 Saudi Arabia
- 11.4.8 Turkey
- 11.4.9 Argentina
- 11.4.9 UAE
- 11.4.9 Egypt
- 11.4.9 Chile
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
- 13.6 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst